36 providers compared•Prices verified October 2, 2026•Scores set by methodology, not payment•Methodology
Cheapest Options

Cheapest GLP-1 medication in 2026Starting at $69/mo, no insurance needed →

Two ways to read “cheapest”

Featured affiliate partner: Embody, a disclosed commercial placement. Payment never changes the price table below. The lowest complete recurring GLP-1 price in our current dataset is $99/mo from Eden Health GLP-1, which we score 6.9/10, so it is the cheapest complete price rather than a recommendation. Only 3 of 36 publish a price we can verify covers everything.

By Price

Cheapest GLP-1 Providers

Sorted by lowest monthly starting price.

We may earn a commission through partner links. Featured placements are reserved for approved partners; this table also includes editorial coverage. Payment does not change scores or the published order. This is a selected comparison, not a complete market survey. Some scores still use earlier assessments; see the methodology limitations. How we rank.

#1

Collective

Our score4.6/10Provisional

Best for: Cash-pay patients planning to stay in treatment long enough for the low flat medication rate to offset the required annual membership

from $59/mo

Medication only, plus $199/year membership after 21 days. Terms also allow an unpriced technology fee.

Price details for Collective

$59/mo is compounded semaglutide medication only. Required membership is free for 21 days, then $199/year; first-year semaglutide totals $907 ($75.58/mo effective). Tirzepatide is $69/mo plus the membership, or $1,027 in year one. The terms also permit an unpriced electronic-prescription technology fee.

Full review and sources
Compounded
What to consider

The $59 and $69 medication headlines exclude a required $199 annual membership after a 21-day trial

Visit CollectiveRead review →
#2Pick

Embody

Our score7.3/10

Best for: People who want to compare Embody's published plan menu with its separate monthly promotion and will confirm the exact charge, term and refund rules before paying

from $69/mo

Not a verified flat checkout price. Catalogue: $828 upfront for 12 months; monthly promo terms differ.

Price details for Embody

The $69 headline is not a flat verified checkout price. The public catalogue lists $79/$129 for one month and $69/$119 monthly equivalents on twelve-month prepay ($828/$1,428). A separate promotion advertises $69/$119 flat monthly, while the still-published April 24 terms list different introductory and fixed-price programs. Which terms apply to the final offer and renewal remains unverified. Sources checked September 27, 2026.

Full review and sources
CompoundedTrustpilot 3.8/5 · 8,121+
What to consider

Payments are normally non-refundable. If Embody's provider determines medical disqualification, its refund policy allows a refund for unused services after deducting services already provided. Cancellation otherwise stops future renewal. The twelve-month semaglutide plan commits $828 up front; cancellation requests must reach support at least 72 hours before the next billing date.

Visit EmbodyRead review →
#3

Maximus

Our score5.1/10

Best for: Men who want GLP-1 alongside testosterone or other men's health protocols

published $79.99/mo

Microdose medication only. Consultation and labs are extra; total not verified.

Price details for Maximus

published microdose medication price; consultation and lab fees are separate, total not verified; standard dosing reaches $299.99/mo

Full review and sources
BothTrustpilot 4.3/5 · 833+
What to consider

The advertised rates are first cycle prices. Compounded semaglutide steps up from $149.99 to $249.99 a month once the first cycle ends, and tirzepatide from $259.99 to $359.99, with lab work billed on top at $99 for the at-home kit or $19.99 to $115 for a Quest draw

Visit MaximusRead review →
#4

Eden Health GLP-1

Our score6.9/10

Best for: People who want a flat $99 a month for compounded semaglutide at every dose, with free expedited shipping and no separate consultation fee on the plan we link to.

$99/mo

month-to-month, from $34 on a plan all-inclusive month-to-month semaglutide, flat at every dose (tirzepatide $129/mo);

Price details for Eden Health GLP-1

all-inclusive month-to-month semaglutide, flat at every dose (tirzepatide $129/mo);

Full review and sources
BothTrustpilot 4.5/5 · 4,627+
What to consider

Eden's current public compounded GLP-1 page advertises $99 a month for semaglutide and $129 for tirzepatide with no separate membership fee. Brand-name treatment pages showed a separate membership charge when last checked September 12, 2026. The affiliate checkout could not be independently read today, so confirm your exact medication, first bill and renewal terms.

Visit Eden Health GLP-1Read review →
#5

Sesame Care

Our score7.9/10

Best for: Users who want cheap FDA-approved brand-name GLP-1 access ($149-349/mo Wegovy and Zepbound via Success by Sesame), or insured patients who just need a prescriber

published $99/mo

Program fee only. Medication is extra; total not verified.

Price details for Sesame Care

published month-to-month program fee; medication is separate, medication-inclusive total not verified

Full review and sources
BrandInsuranceTrustpilot 4.5/5 · 3,100+
What to consider

Sesame runs three separate routes under one brand: the Success by Sesame weight loss subscription, EverydayRx for diabetes, and one-off visits from $34. Check which one you are signing up for before you pay.

Visit Sesame CareRead review →
What the types mean: Brand = FDA-approved name-brand (Wegovy, Zepbound, Ozempic). Compounded = pharmacy-prepared semaglutide/tirzepatide that is not FDA-approved and should not be assumed equivalent to a brand product. Both = offers brand-name and compounded.

How many GLP-1 programs publish a price you can actually rely on?

3 of 36. We checked the published pricing of every GLP-1 telehealth program in our index. Only 3 advertise a headline price where the provider itself documents that both the consultation and the delivery are included. Every other number on this page is an entry rate, a promotional rate, a membership that bills the drug separately, or a total we could not confirm.

This is not an accusation of dishonesty. It is how the category advertises. It does mean the advertised number is rarely the number you pay, and it is the reason we label what each price actually is instead of sorting everyone into one column and calling it a comparison.

What the 36 advertised prices actually are

  • 5Publish a total we could not confirmThe program advertises a monthly number, but its own published terms do not let us confirm what that number includes.
  • 1Charge a membership that excludes the medicationThe headline figure buys access to the clinician and the platform. The drug is billed on top, often through insurance or a pharmacy of their choosing.
  • 2Bill the medication on top of a program feeTwo separate charges, and only one of them appears in the advertised price.
  • 3Advertise a first-month rate that risesThe number you see is a promotion. Month two costs more, sometimes several times more.
  • 22Advertise a "from" priceAn entry tier: the cheapest dose, the longest prepaid commitment, or a specific medication. Most people do not pay it.
  • 3Publish one ongoing monthly rateA single recurring number with no commitment ladder underneath it.

See which programs fall into each category. Counts are derived from our provider records at build time, so they move when a provider's pricing moves. 36 of the 36 carry a dated price check, most recently 2026-10-02. Where we could not confirm a total we say so on the provider's own row rather than estimating one. Our scoring methodology treats price transparency as a graded dimension, not a footnote.

Independently researched. Every statistic links to a primary source, see our editorial policy. Affiliate status never changes a provider's score (featured picks are disclosed). Last verified October 2026.
Featured Affiliate Partner
Embody, from $69/mo

Commercial placement selected from active affiliate partners. Objective price order and methodology scores remain separate.

7.3/10 score. People who want to compare Embody's published plan menu with its separate monthly promotion and will confirm the exact charge, term and refund rules before paying

Read our full Embody review →
Visit Embody

All 36 tracked providers, sorted by their published headline figure. Introductory rates, membership fees, separate charges, and unresolved totals are labeled in the table.

Shopping by medication instead of price? See every verified semaglutide program, tirzepatide program, or microdose GLP-1 tier compared form-by-form.

Arrived here from a named program rather than a price? Readers searching Embody tirzepatide reviews land on a single-program page that carries its compounded injection and oral gum tiers, and it sits at rank 17 of 36 in the table below rather than at the top of it.

Buying at the low end usually means buying compounded, so it is worth knowing what has been pulled back from that supply chain. We assembled the semaglutide recall record from FDA enforcement data: sterility and ingredient-validation failures at compounders and raw-ingredient makers, each row linked to its FDA recall number.

Where a row is explicitly labeled all-in, the published price covers:

  • •The medication
  • •Consultations
  • •Membership or platform fees
  • •Shipping

Avoiding extra fees or a large upfront bill? Compare semaglutide plan fees or tirzepatide fees and prepayment.

Not sure which one? Take the 60-second quiz →Compare semaglutide prices →Compare tirzepatide prices →Tirzepatide Cost Breakdown →Oral GLP-1 Pills (No Injection) →
On Medicare? GLP-1 Bridge Demonstration Now Live (July 1, 2026)

As of July 1, 2026, Medicare Part D covers brand-name Wegovy, Zepbound, and Foundayo at a $50/month flat copay through the Medicare GLP-1 Bridge Demonstration (active through December 31, 2027). Eligibility: BMI 35+, or BMI 27+ with cardiovascular disease, prediabetes, or hypertension. If you qualify, $50/mo brand-name beats most compounded self-pay options on this page.

See our Medicare GLP-1 coverage guide for eligibility details, enrollment steps, and how the Bridge compares to commercial insurance coverage. Foundayo is a once-daily pill with no fasting required. For a head-to-head comparison of the two oral options at $50/mo, see our oral GLP-1 pill guide.

Will switching GLP-1 providers actually save money?

Compare the bill you can leave with the bill you would start, not just two advertised monthly prices. Write down the new first payment, renewal amount, medication and care fees, plus any old charge you cannot cancel. Count a prepaid refund only after the provider confirms it. A lower monthly equivalent can still require a larger payment today.

Use the provider-switching handover and billing checklist before changing services. It separates records, prescribing and pharmacy questions from subscription cancellation, so a cheaper quote is not mistaken for an approved treatment plan.

Frequently asked questions

Frequently Asked Questions

What is the cheapest GLP-1 medication in 2026?+
The lowest complete, non-intro recurring program price we currently track is $99/month at Eden Health GLP-1. Compounded semaglutide products are not FDA-approved, their formulation and source can vary, and readers should verify the dispensing pharmacy and prescription details rather than assume equivalence to Ozempic or Wegovy. The cheapest medication-inclusive brand-name option we list is LillyDirect Zepbound at $299/mo (tirzepatide, direct from the manufacturer). Lower brand-program figures may be platform or membership fees with medication billed separately or through insurance.
Is the cheapest option safe?+
Price alone does not establish that a program or medication is safe. We publish FDA warning-letter findings and named-pharmacy details when we can verify them, and label missing evidence rather than treating it as a clean record. Check the provider's current pharmacy and prescribing process, review our Safety Checker, and discuss the choice with your clinician before enrolling.
What does 'all-in' mean?+
All-in means the published recurring amount includes medication and any required program or membership fee. The page's headline and cheapest structured list use only complete, non-intro recurring prices. The full table also shows first-month promotions, membership-only fees, and totals that are still being verified, but labels those limitations beside the number.
How do you verify these prices?+
We check provider websites, pricing pages, checkout disclosures, and available partner reporting, then store a provider-specific verification date. Not every program publishes a complete all-in total, so unresolved figures stay labeled and are excluded from the all-in price floor. See our editorial policy and each provider review for the evidence date and tier details.
Why no insurance?+
This page shows cash-pay options because most commercial insurance plans don't cover compounded GLP-1 medications, and Wegovy/Zepbound brand-name coverage varies widely by plan. Some Part D enrollees may qualify for a $50 copay through the separate Medicare GLP-1 Bridge after authorization. It operates outside regular Part D coverage; eligibility depends on clinical criteria, indication and treatment history. If you want to use commercial insurance, check our insurance lookup tool or ask Ro or Fridays about brand-medication coverage and prior-authorization help. Program fees may still be cash-pay.
Are affiliate partners ranked higher?+
No. This page is sorted purely by comparable price, and our main ranking table is sorted purely by methodology score. A provider's score comes entirely from our published methodology (Pricing 25%, Clinical Oversight 25%, Medication Options 20%, UX 15%, Transparency 15%) and is never influenced by payment. Affiliate partners are marked with emerald CTA buttons for transparency.
Common questions

Best compounded semaglutide & tirzepatide providers (2026): a legitimacy-first guide

A legitimate compounded GLP-1 provider names the exact pharmacy that fills your prescription and tells you whether it's a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, pairs you with a US-licensed prescriber, and can show third-party credentials: LegitScript certification, PCAB accreditation (which audits against US Pharmacopeia compounding standards USP <795>/<797>), and a Certificate of Analysis confirming the active ingredient is true semaglutide or tirzepatide base. The ranked compounded picks in the table above are scored on exactly these signals, not on the lowest sticker price. That distinction matters more in 2026 than ever: compounded drugs are not FDA-approved and the FDA does not review them for safety, effectiveness, or quality, and the agency has moved to close most remaining legal pathways. Below is what separates a defensible compounded provider from a risky one, the current regulatory status, and the exact questions to ask before you pay.

What makes a compounded semaglutide or tirzepatide provider legitimate versus risky?+
Six concrete signals, all verifiable before you pay. (1) A named pharmacy. A legitimate provider tells you which pharmacy compounds your medication and whether it's a 503A (state-licensed, patient-specific) pharmacy or a 503B (FDA-registered outsourcing facility); a provider that hides the pharmacy name is a red flag. (2) Third-party credentials: LegitScript certification (which verifies the merchant complies with applicable laws and is the standard that lets a telehealth pharmacy advertise on Google and Meta) and PCAB accreditation, awarded by ACHC, which audits a pharmacy against US Pharmacopeia compounding standards USP <795> (non-sterile) and USP <797> (sterile injectables). (3) A Certificate of Analysis (CoA) on the active ingredient, confirming it is true semaglutide or tirzepatide base, not a salt form. (4) A US-licensed prescriber who reviews your history rather than a checkbox form. (5) Transparent, all-in pricing with no bait intro rate. (6) Clear labeling, dosing instructions, and a way to report side effects. Risk signals: no pharmacy named, no prescriber consult, salt-form ingredients, prices that look too good to be true, and dosing 'protocols' that exceed FDA-approved labeling. The FDA warns that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality.
What's the difference between a 503A and a 503B compounding pharmacy?+
A 503A pharmacy is a traditional, state-licensed pharmacy that compounds a medication for an individual patient based on a specific prescription. A 503B outsourcing facility registers with the FDA, is inspected by the FDA on a risk-based schedule, and follows current Good Manufacturing Practice (CGMP) standards, so it can compound larger batches. Neither produces an FDA-approved drug, but a 503B operates under more federal oversight. When a provider names its pharmacy, you can look up the facility: 503B outsourcing facilities appear on the FDA's public registered-facilities list. Whether a provider uses 503A or 503B, the legitimacy questions are the same: is the pharmacy named, is it accredited, and can you see a Certificate of Analysis on the API?
Is compounded semaglutide or tirzepatide even legal in 2026?+
It's narrowly legal and shrinking. The FDA removed semaglutide and tirzepatide from the drug shortage list in early 2025, which ended the broad enforcement window that had allowed mass compounding. As of 2026, 503A pharmacies may still compound on a patient-specific basis only in limited situations, such as a documented allergy to an inactive ingredient in the brand product or a need for a dose strength that isn't commercially available; the FDA has been explicit that lower cost or greater convenience do not, by themselves, establish a 'clinical need.' For 503B outsourcing facilities, in April 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List after finding no clinical need to compound them from bulk substances; the public comment period on that proposal closed July 30, 2026 (Docket FDA-2018-N-3240), after an extension from June 29 via FR 2026-12937. Bottom line: a 'compounded GLP-1' offered purely because it's cheaper, with no patient-specific justification, sits in a legally exposed gray zone. Always confirm a provider's pharmacy and prescriber are operating within these rules.
Why does the salt-form issue matter, and what is a Certificate of Analysis?+
The FDA has flagged that some compounders use semaglutide sodium or semaglutide acetate, which the agency considers different active ingredients from the semaglutide base used in approved drugs (Ozempic, Wegovy). The FDA has stated there is no evidence these salt forms are safe or effective for this use and no legal basis for using them in compounding. A Certificate of Analysis (CoA) is a lab document from the pharmacy or its API supplier confirming the identity, purity, and potency of the active ingredient in your specific product. A legitimate provider can supply one on request and it should show semaglutide base (or tirzepatide), not a salt form. If a provider can't or won't produce a CoA, treat that as a stop sign.
What are the real safety risks the FDA has documented with compounded GLP-1s?+
Two stand out. First, dosing errors: the FDA has reported cases where patients accidentally administered five to twenty times the intended dose after drawing medication from multi-dose vials, often because of confusion between 'units,' milliliters, and milligrams, with some cases requiring hospitalization. Brand pens are pre-measured; compounded vials usually are not, so the burden is on you to measure correctly. Second, the FDA has received adverse-event reports tied to compounded products, including reports involving doses beyond FDA-approved labeling. A legitimate provider mitigates the dosing risk with clear instructions, properly labeled syringes, and prescriber guidance. None of this makes brand-name GLP-1s automatically right for you either, but it explains why we weight clinical oversight and pharmacy transparency heavily in our scoring rather than ranking purely by price. See our full safety center and the per-provider reviews for how each one handles this.
How should I choose between a compounded provider and a brand-name GLP-1?+
Start with eligibility and oversight, then price. Brand-name Wegovy and Zepbound are FDA-approved, pre-dosed, and increasingly available through manufacturer cash programs (for example, LillyDirect Zepbound) and, for some Medicare Part D members, the Part D coverage pathway. Compounded versions can cost meaningfully less but are not FDA-approved, are legal only in narrow patient-specific circumstances in 2026, and put more responsibility on the provider and pharmacy to get safety right. If you go compounded, only use a provider that names an accredited pharmacy, uses a US-licensed prescriber, and can produce a Certificate of Analysis. Use our scored rankings table above to compare, use the homepage finder to compare medication and format options, and read the individual /reviews for the pharmacy and prescriber details behind each provider. This is general information, not medical advice; talk to a licensed clinician about what's right for you.

Sources: FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (not FDA-approved; salt forms; not reviewed for safety/effectiveness/quality) · FDA, Alert: Dosing Errors Associated with Compounded Injectable Semaglutide Products (5-20x intended dose; units/mL/mg confusion; multi-dose vials) · FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 2026; no clinical need; cost/convenience not 'clinical need') · Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (comment period closed July 30, 2026, extended from June 29 via FR 2026-12937, Docket FDA-2018-N-3240) · FDA, Compounding and the FDA: Questions and Answers (503A vs 503B definitions; 503B registration, inspection, CGMP) · ACHC / PCAB, PCAB Accreditation for Compounding Pharmacies (USP <795> non-sterile, USP <797> sterile standards) · LegitScript, Healthcare Certification (merchant/telehealth/pharmacy compliance verification)

Every provider’s full pricing record

The tables above rank by headline price. Each record below carries the complete tier breakdown, the date we last verified it on the provider’s own site, first-year math where we can compute it honestly, and any promotion our weekly automated sweep detected on their pages. All 36 programs we track have one, including the ones with no comparable all-in price to rank above.

Still not sure which provider is right for you?

Our 60-second match quiz asks 7 questions and recommends the best GLP-1 provider for your budget, medication preference, and insurance situation.

Take the Match Quiz →

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Embody

7.3/10
from $69/mo·Compounded
Visit EmbodyReview

Gala

7.2/10
from $149/mo·Brand & Compounded

Microdose offer on a 3-month subscription. Confirm the full checkout total.

Visit GalaReview

Ro

7.2/10
$149/mo membership + medication·Brand
Visit RoReview

Fridays

8.7/10
from $117/mo·Brand & Compounded

Annual semaglutide plan with code NYNY12; $279 month-to-month.

Visit FridaysReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at GLP-1 Picks comparison.

Top PickEmbody · from $69/moGet →